William H. Marshall V^1,2,*, Lydia K. Wright²

Congenital Heart Disease, Vol.19, No.4, pp. 419-433, 2024, DOI:10.32604/chd.2024.056608 - 31 October 2024

Abstract Heart failure (HF) is common in patients with congenital heart disease (CHD) and there are limited medical therapies. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a proven medical therapy in patients with acquired HF, though data are limited in patients with CHD. The aim of this review is to summarize the current evidence for use of SGLT2i in patients with CHD and identify future directions for study. In available publications, SGLT2i in patients with CHD seem to be well tolerated, with similar side effect profile to patients with acquired HF. Improvement in functional capacity and natriuretic More >

Margaret M. Samyn^1,2, Ke Yan¹, Conor Masterson³, Benjamin H. Goot^1,2, David Saudek^1,2, Julie Lavoie², Aaron Kinney², Mary Krolikowski¹, Kan Hor^4,5, Scott Cohen^1,2

Congenital Heart Disease, Vol.14, No.6, pp. 1138-1148, 2019, DOI:10.1111/chd.12861

Abstract Objective: Patients with Dextro-transposition of the great arteries status post atrial switch (dTGA s/p atrial switch) are “at-risk” for systemic right ventricular (RV) dysfunction. Due to complex RV geometry, echocardiography (Echo) does not allow accurate determination of ejection fraction (EF), but cardiac magnetic resonance imaging (CMR) allows quantitative right ventricular assessment. Measures of ventricular deformation may be precursors to global ventricular dysfunction. The primary aim of this study was to characterize imaging and clinical findings for adult patients with dTGA s/p atrial switch.
Design: This was a retrospective cohort study of patients with dTGA s/p atrial switch… More >